Phase Ib Study of Afuresertib Combined With Paclitaxel in Pre-treated HER2-negative Advanced Gastric Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Apr 2017
Price : $35 *
At a glance
- Drugs Afuresertib (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 31 Aug 2018 Biomarkers information updated
- 07 Apr 2017 Status changed from recruiting to completed.
- 19 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.